Karol A Sadowski, Malwina Gonet, Zofia Dzielińska, Piotr Kołsut, Jarosław Kuriata, Michał Kania, Gary S Mintz, Stephanie L Sellers, David Meier, Marcin Demkow, Łukasz Kalińczuk
{"title":"Leaflet Folding Due to Transcatheter Heart Valve Underexpansion Detected by IVUS During Mitral Valve-in-Valve Replacement.","authors":"Karol A Sadowski, Malwina Gonet, Zofia Dzielińska, Piotr Kołsut, Jarosław Kuriata, Michał Kania, Gary S Mintz, Stephanie L Sellers, David Meier, Marcin Demkow, Łukasz Kalińczuk","doi":"10.1016/j.jcin.2025.06.015","DOIUrl":"https://doi.org/10.1016/j.jcin.2025.06.015","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":" ","pages":""},"PeriodicalIF":11.7,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Breaking Bicuspid: When Less Is More and 0 Beats 1 (and 3).","authors":"Giuseppe Tarantini","doi":"10.1016/j.jcin.2025.05.046","DOIUrl":"https://doi.org/10.1016/j.jcin.2025.05.046","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":" ","pages":""},"PeriodicalIF":11.7,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR.","authors":"Weiya Li, Yuheng Jia, Hongde Li, Yusuke Kobari, Junli Li, Yuan Feng, Yong Peng, Jiafu Wei, Zhengang Zhao, Tianyuan Xiong, Haoran Yang, Chengxiang Song, Wenhua Lei, Shiqin Peng, Yue Yin, Xuechen Qiao, Duolao Wang, Won-Keun Kim, Ole De Backer, Mao Chen","doi":"10.1016/j.jcin.2025.05.045","DOIUrl":"https://doi.org/10.1016/j.jcin.2025.05.045","url":null,"abstract":"<p><strong>Background: </strong>Differences in long-term clinical outcomes following transcatheter aortic valve replacement (TAVR) in different anatomical subtypes of aortic valve stenosis (AS), specifically tricuspid aortic valves (TAV) and bicuspid aortic valves (BAV) of types 0 (BAV-0) and 1 (BAV-1), are not well understood.</p><p><strong>Objectives: </strong>We sought to report and compare the long-term clinical outcomes among patients with different anatomical subtypes of AS undergoing TAVR.</p><p><strong>Methods: </strong>We conducted an international retrospective cohort study involving patients who underwent TAVR for severe AS at 3 large, high-volume heart centers in China, Germany, and Denmark before October 2018. Five-year follow-up ended on October 30, 2023, and the primary endpoint was all-cause mortality.</p><p><strong>Results: </strong>A total of 2,553 AS patients (BAV-0: n = 134; BAV-1: n = 305; TAV: n = 2,114) who underwent TAVR more than 5 years ago were included. The mean age of this cohort was 79.9 ± 6.8 years, and the median Society of Thoracic Surgeons score was 3.6% [Q1-Q3: 2.4%-5.4%]. The median follow-up time was 3.24 years (Q1-Q3: 1.25-5.00 years). At 5 years, BAV-1 (adjusted HR: 2.38 [95% CI: 1.32-4.28]; P = 0.004) and TAV (adjusted HR: 3.02 [95% CI: 1.71-5.31]; P < 0.001) had a higher risk for all-cause mortality after TAVR compared with BAV-0. BAV patients who were treated with balloon-expandable valves had a higher long-term all-cause mortality (41.7% [28.5%-52.5%] vs 23.6% [17.9%-28.8%]; HR: 1.63 [95% CI: 1.05-2.51]; P = 0.028) compared with those with self-expanding valves.</p><p><strong>Conclusions: </strong>Among patients with severe AS undergoing TAVR, BAV-0 was associated with a better long-term prognosis compared with TAV and BAV-1.</p>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":" ","pages":""},"PeriodicalIF":11.7,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carlos A Gonzalez Lengua, Chirag Lodha, Howard Tee, John Lindenthal, James Wudel, Mauricio Cohen
{"title":"Percutaneous Mechanical Aspiration of Transcatheter Aortic Valve Vegetation.","authors":"Carlos A Gonzalez Lengua, Chirag Lodha, Howard Tee, John Lindenthal, James Wudel, Mauricio Cohen","doi":"10.1016/j.jcin.2025.05.023","DOIUrl":"https://doi.org/10.1016/j.jcin.2025.05.023","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":" ","pages":""},"PeriodicalIF":11.7,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Krishnaraj S. Rathod PhD , Katrina Comer BSc , Oliver Casey-Gillman MSc , Lizzie Moore MSc , Sotiris Antoniou MRPharmS, MSc , Sadeer Fhadil MPharm , Paul Wright MPharm, MSc , Jennifer Mather BSc , Michelle C.T. Yick MD , Rohan Vyas MD , Roy B. Wang MD , Muhiddin A. Ozkor MD , Oliver P. Guttmann MD , Andreas Baumbach MD , R. Andrew Archbold MD , Andrew Wragg PhD , Ajay K. Jain MD , Fizzah A. Choudry PhD , Anthony Mathur PhD , Daniel A. Jones PhD
{"title":"Cost-Effectiveness of Early Discharge (<48 Hours) for Low-Risk Patients Following PPCI for STEMI","authors":"Krishnaraj S. Rathod PhD , Katrina Comer BSc , Oliver Casey-Gillman MSc , Lizzie Moore MSc , Sotiris Antoniou MRPharmS, MSc , Sadeer Fhadil MPharm , Paul Wright MPharm, MSc , Jennifer Mather BSc , Michelle C.T. Yick MD , Rohan Vyas MD , Roy B. Wang MD , Muhiddin A. Ozkor MD , Oliver P. Guttmann MD , Andreas Baumbach MD , R. Andrew Archbold MD , Andrew Wragg PhD , Ajay K. Jain MD , Fizzah A. Choudry PhD , Anthony Mathur PhD , Daniel A. Jones PhD","doi":"10.1016/j.jcin.2025.04.045","DOIUrl":"10.1016/j.jcin.2025.04.045","url":null,"abstract":"<div><h3>Background</h3><div>Early discharge after primary percutaneous coronary intervention can increase the efficiency of health care, enabling cost savings. Dedicated virtual follow-up pathways can provide remote diagnostic information to aid earlier discharge, optimize care and reduce unplanned readmissions.</div></div><div><h3>Objectives</h3><div>The aims of this study were: 1) to review the long-term (1-year) safety of early hospital discharge (<48 hours) after ST-segment elevation myocardial infarction; 2) to assess the effect of virtual follow-up on medication adherence and ability to up-titrate secondary prevention medication; and 3) to determine the cost-effectiveness of a virtual follow-up pathway after early discharge.</div></div><div><h3>Methods</h3><div>Between April 2020 and March 2023, 1,500 low-risk patients were discharged at <48 hours and placed on the early hospital discharge follow-up pathway. Patients were reviewed by structured virtual follow-up at 48 hours; 2, 4, and 8 weeks; and 3 and 12 months.</div></div><div><h3>Results</h3><div>The median length of hospital stay was 24.9 hours (Q1-Q3: 22.8-36.4 hours), with a minimum of 17 hours and a maximum of 40 hours. Seventy-three percent of patients (1,095 of 1,500) stayed 1 fewer night in the hospital compared with normal pathways. The median length of stay for the control group was 68.1 hours (Q1-Q3: 56-80 hours) (<em>P</em> < 0.0001). During 12-month follow-up, there was a low major adverse cardiac event rate of 3.1% (47 of 1,500) including 0.6% (9 of 1,500) for all-cause mortality and 0.13% (2 of 1,500) for cardiovascular mortality in the early hospital discharge group, which compared favorably with the >48-hour control group (major adverse cardiac event rate 5.5% [77 of 1,400]; <em>P</em> = 0.043).</div></div><div><h3>Conclusions</h3><div>Selected low-risk patients can be discharged securely and safely following successful primary percutaneous coronary intervention using a pathway that is reinforced by a formal, multidisciplinary virtual follow-up program, enabling improvements in medication adherence and up-titration.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 12","pages":"Pages 1499-1509"},"PeriodicalIF":11.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"15-Year Outcomes of PFO Closure in Patients With Cryptogenic Embolism","authors":"Carlo Gaspardone MD , Daniela Trabattoni MD , Daniele O. d’Atri MD , Michele Morosato MD , Paolo Costa MD , Chiara Fraccaro MD, PhD , Andrea Donti MD , Francesco Saia MD, PhD , Evelina Toscano MD , Filippo Scalise MD , Alessio Cucco MD , Giuseppe Patti MD , Roberto Nerla MD , Fausto Castriota MD , Carlo Trani MD , Riccardo Improta MD , Massimo Mancone MD, PhD , Gennaro Sardella MD , Carmine Musto MD, PhD , Maurizio Paciaroni MD , Cosmo Godino MD","doi":"10.1016/j.jcin.2025.04.041","DOIUrl":"10.1016/j.jcin.2025.04.041","url":null,"abstract":"<div><h3>Background</h3><div>Transcatheter patent foramen ovale (PFO) closure has become the gold-standard treatment for patients with cryptogenic embolism and PFO, but long-term outcomes data are limited.</div></div><div><h3>Objectives</h3><div>The aim of this study was to report the extended clinical outcomes of patients who underwent transcatheter PFO closure for cryptogenic embolism.</div></div><div><h3>Methods</h3><div>PROLONG (PFO Transcatheter Occlusion Long-Term Outcomes National Group) is an investigator-initiated, multicenter, retrospective registry that enrolled patients who underwent transcatheter PFO closure between 1999 and 2013 at 12 centers in Italy. This analysis included only patients who underwent PFO closure for cryptogenic embolism, defined as cryptogenic ischemic stroke, transient ischemic attack, systemic embolism, or silent ischemic lesions on magnetic resonance imaging. Clinical, imaging, procedural, and follow-up data were collected from electronic health records and telephone interviews.</div></div><div><h3>Results</h3><div>The study included 1,245 patients (mean age 47 ± 12 years, 56% women), with a mean follow-up duration of 14.5 ± 2.4 years. During follow-up, 34 patients (2.7%) experienced recurrent ischemic stroke, transient ischemic attack, or systemic embolism (0.19 per 100 patient-years). Predictors of recurrent events were Risk of Paradoxical Embolism (RoPE) score ≤ 7 (HR: 3.44; 95% CI: 1.06-11.3; <em>P</em> = 0.041), nonprobable PFO-Associated Stroke Causal Likelihood (PASCAL) classification (HR: 2.72; 95% CI: 1.17-6.34; <em>P</em> = 0.020), and new-onset atrial fibrillation (HR: 7.01; 95% CI: 2.45-20.1; <em>P</em> < 0.001). Serious complications were rare (0.4% in hospital, 0.4% during follow-up) and nonfatal.</div></div><div><h3>Conclusions</h3><div>This study confirms the long-term efficacy and safety of transcatheter PFO closure for patients with cryptogenic embolism and PFO in a real-world setting. (PFO Transcatheter Occlusion Long-Term Outcomes National Group [PROLONG] Registry; <span><span>NCT06504121</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 12","pages":"Pages 1526-1537"},"PeriodicalIF":11.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Too Soon to Go Home After a STEMI?","authors":"Christian Spaulding MD, PhD , Tanios Akiki MD","doi":"10.1016/j.jcin.2025.05.015","DOIUrl":"10.1016/j.jcin.2025.05.015","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 12","pages":"Pages 1510-1511"},"PeriodicalIF":11.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}